Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Germline genetic contribution to the immune landscape of cancer

Immunity(2021)10.1016/j.immuni.2021.01.011Source: DataRank Database

Germline genetic contribution to the immune landscape of cancer is a research paper published in Immunity (2021). On theSindex it has a DataRank of 4.2. It has been cited 178 times, with 152 citing works in its 1-hop citation network.

N/A

4.2DataRank · unranked

Scored on demand from live citation data

Open Access178 citations · 152 citing works in its network

Download PDF

Cite:

Linked data & code

refsnp dbgap doi pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 11.12)OA: bronzeTopics (104)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 18%Citation Network 82%

Base Score Contribution

0.778

From this paper's citation signal

Citation Network Contribution

3.4

From 113 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 152 citers.

Decoding the genetic basis of anti-tumor immunity
Immunity20217 citations11 referencesContributes 0.189
Seed or soil: Tracing the immune subsets in metastatic tumors
Cancer Cell20224 citations9 referencesContributes 0.179
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
Journal of Experimental & Clinical Cancer Research202224 citations23 referencesContributes 0.140
Immune phenotypic linkage between colorectal cancer and liver metastasis
Cancer Cell2022474 citations47 referencesContributes 0.131
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function
OncoImmunology202317 citations24 referencesContributes 0.120

Authors (26)

Mohamad Saad ORCID,Vésteinn Thórsson ORCID,Donglei Hu ORCID,Wouter Hendrickx ORCID,Jessica Roelands ORCID

Live enrichment

PubMed:33567262 PMC:PMC8414660 OpenAlex:https://openalex.org/W3127961017

Associazione Italiana per la Ricerca sul Cancro

Grant: IG2018-21846

National Institutes of Health

Grant: K24CA169004

National Institutes of Health

Grant: R01CA227466

National Institutes of Health

Grant: T32CA221709

Qatar National Research Fund

Grant: NPRP11S-0121-180351

Qatar National Research Fund

Grant: SDR100035

Qatar National Research Fund

Grant: SDR400023

National Institutes of Health

Grant: 5K24CA169004-03

Genetic and Epidemiological Approaches to Breast Density and Breast Cancer Risk

National Institutes of Health

Grant: 5T32CA221709-02

Cancer Metabolism Training Program

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5R01CA227466-03

(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy

Institut National de la Santé et de la Recherche Médicale

AbbVie

Sanofi

Cancer Research Institute

Janssen Biotech

AstraZeneca

MedImmune

FWCI

11.12

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttp://www.cell.com/article/S1074761321000340/pdf

publisherhttp://www.cell.com/article/S1074761321000340/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1074761321000340?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1074761321000340?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.immuni.2021.01.011

Fields of Study

Cancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCancer-related molecular mechanisms research0301 basic medicine03 medical and health sciencesDatabases, GeneticFemaleGene Expression Regulation, NeoplasticGenes, BRCA1Genome-Wide Association StudyGerm-Line MutationHumansImmunotherapyInterferonsKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasmsQuantitative Trait, HeritableRetinoblastoma-Like Protein p107Signal TransductionT-LymphocytesWnt Proteinsbeta Catenin

MeSH Terms

FemaleHumansImmunotherapyInterferonsKiller Cells, NaturalMaleMiddle AgedNeoplasmsT-LymphocytesSignal TransductionGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingGerm-Line MutationGenes, BRCA1Quantitative Trait, HeritableDatabases, GeneticRetinoblastoma-Like Protein p107Wnt Proteinsbeta CateninGenome-Wide Association Study

Keywords

BiologyGermlineCancerImmune systemGeneticsEvolutionary biologyComputational biologyGeneHeritabilityCancer ImmunotherapyGwasCancer ImmunityTcgaRare Variant AnalysisGermline GeneticsImmune SubtypesCancer Immune LandscapeIatlasMaleT-LymphocytesGenes, BRCA1Retinoblastoma-Like Protein p107Àrees temàtiques de la UPC::Informàtica::Aplicacions de la informàtica::BioinformàticaNeoplasmsDatabases, GeneticKiller Cells2.1 Biological and endogenous factorsLymphocytesAetiologyCàncer -- Aspectes genèticsbeta Catenincancer immune landscape; cancer immunity; Cancer immunotherapy; germline genetics; GWAS; heritability; iATLAS; Immune subtypes; rare variant analysis; TCGAMiddle AgedGene Expression Regulation, NeoplasticKiller Cells, NaturalNaturalFemaleImmunotherapySignal TransductionImmunologyQuantitative TraitDatabasesLymphocytes, Tumor-InfiltratingQuantitative Trait, HeritableGeneticTumors--Immunological aspectsHumansTumor-InfiltratingHeritableGerm-Line MutationNeoplasticHuman GenomeBRCA1Wnt ProteinsGood Health and Well BeingGene Expression RegulationGenesInterferonsGenome-Wide Association Study

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445380.v1figshare

Additional file 1 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445380figshare

Additional file 4 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445389.v1figshare

Additional file 4 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445389figshare

Additional file 2 of Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes

10.6084/m9.figshare.26649168.v1figshare

Additional file 2 of Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes

10.6084/m9.figshare.26649168figshare

Additional file 1 of Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes

10.6084/m9.figshare.26649165.v1figshare

Additional file 1 of Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes

10.6084/m9.figshare.26649165figshare

Additional file 2 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445383.v1figshare

Additional file 2 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445383figshare

Additional file 3 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445386.v1figshare

Additional file 3 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

10.6084/m9.figshare.19445386figshare